Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IACS-13909 |
Synonyms | |
Therapy Description |
IACS-13909 binds to and inhibits the phosphatase activity of Shp2, inhibits signaling through the MAPK pathway, potentially inhibiting cell proliferation and tumor growth (PMID: 32928921). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IACS-13909 | IACS13909|IACS 13909 | SHP2 Inhibitor 20 | IACS-13909 binds to and inhibits the phosphatase activity of Shp2, inhibits signaling through the MAPK pathway, potentially inhibiting cell proliferation and tumor growth (PMID: 32928921). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | IACS-13909 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, IACS-13909 decreased Erk phosphorylation and inhibited proliferation in a acute myeloid leukemia cell line harboring a FLT3-ITD in culture, and inhibited tumor growth and increased overall survival in cell line xenograft models (PMID: 32928921). | 32928921 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|